Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences has entered a definitive agreement to acquire Arcellx, Inc. in a cash deal valued at $7.8b. The transaction expands Gilead's presence in oncology and cell therapy, areas that differ from its core HIV franchise. For investors watching NasdaqGS:GILD, this move comes as the shares trade around $150.03, with a 1 year return of 33.0% and a 3 year return of 105.6%. Over 5 years, the stock shows a very large gain of 180.7%, and the company currently carries a value score of 4, which may catch the eye of value focused investors. This acquisition reflects Gilead increasing its focus on high value cancer therapies and cell based treatments, which may influence how its business mix develops over time. As the deal progresses, investors will likely watch how Gilead integrates Arcellx's pipeline and capabilities into its existing oncology platform and how
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences (GILD) Registers a Bigger Fall Than the Market: Important Facts to Note [Yahoo! Finance]Yahoo! Finance
- Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia [Yahoo! Finance]Yahoo! Finance
- Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of ColumbiaBusiness Wire
- 3T Biosciences Appoints Rebeca Villarreal-Barragan, MBA, as Head of Clinical Operations [Yahoo! Finance]Yahoo! Finance
- Assessing Gilead Sciences (GILD) Valuation As Recent Share Price Momentum Meets Conflicting Fair Value Signals [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- GILD's page on the SEC website